Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thürlimann B, Vergote I, Christodoulou E, Van Calster B, Neven P. Van Asten K, et al. Among authors: weltens c. Oncologist. 2019 Feb;24(2):165-171. doi: 10.1634/theoncologist.2018-0176. Epub 2018 Aug 31. Oncologist. 2019. PMID: 30171067 Free PMC article.
Radiotherapy-specific quality indicators at national level: How to make it happen.
Vaandering A, Jansen N, Weltens C, Moretti L, Stellamans K, Vanhoutte F, Scalliet P, Remouchamps V, Lievens Y; Belgian College for Physicians in Radiation Oncology. Vaandering A, et al. Among authors: weltens c. Radiother Oncol. 2023 Jan;178:109433. doi: 10.1016/j.radonc.2022.11.022. Epub 2022 Dec 1. Radiother Oncol. 2023. PMID: 36464181 Free article.
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
Morales L, Timmerman D, Neven P, Konstantinovic ML, Carbonez A, Van Huffel S, Ameye L, Weltens C, Christiaens MR, Vergote I, Paridaens R. Morales L, et al. Among authors: weltens c. Ann Oncol. 2005 Jan;16(1):70-4. doi: 10.1093/annonc/mdi021. Ann Oncol. 2005. PMID: 15598941 Free article. Clinical Trial.
New trends in radiotherapy for breast cancer.
Van Limbergen E, Weltens C. Van Limbergen E, et al. Among authors: weltens c. Curr Opin Oncol. 2006 Nov;18(6):555-62. doi: 10.1097/01.cco.0000245327.42281.9f. Curr Opin Oncol. 2006. PMID: 16988575 Review.
Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
Neven P, Paridaens R, Amant F, Wildiers H, Berteloot P, Leunen K, Smeets A, Weltens C, van den Bogaert W, van Limbergen E, Christiaens MR, Vergote I. Neven P, et al. Among authors: weltens c. Int J Gynecol Cancer. 2006;16 Suppl 2:505-10. doi: 10.1111/j.1525-1438.2006.00682.x. Int J Gynecol Cancer. 2006. PMID: 17010059 Review. No abstract available.
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Van Limbergen E, Weltens C, Van den Bogaert W, De Smet L, Vergote I, Christiaens MR, Neven P. Morales L, et al. Among authors: weltens c. Breast Cancer Res Treat. 2007 Jul;104(1):87-91. doi: 10.1007/s10549-006-9394-6. Epub 2006 Oct 24. Breast Cancer Res Treat. 2007. PMID: 17061044
Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
Neven P, Van Calster B, Van den Bempt I, Van Huffel S, Van Belle V, Hendrickx W, Decock J, Wildiers H, Paridaens R, Amant F, Leunen K, Berteloot P, Timmerman D, Van Limbergen E, Weltens C, Van den Bogaert W, Smeets A, Vergote I, Christiaens MR, Drijkoningen M. Neven P, et al. Among authors: weltens c. Breast Cancer Res Treat. 2008 Jul;110(1):153-9. doi: 10.1007/s10549-007-9687-4. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687649
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S, Hendrickx W, Decock J, Huang HJ, Leunen K, Amant F, Berteloot P, Paridaens R, Wildiers H, Van Limbergen E, Weltens C, Timmerman D, Van Gorp T, Smeets A, Van den Bogaert W, Vergote I, Christiaens MR, Neven P. Van Calster B, et al. Among authors: weltens c. Breast Cancer Res Treat. 2009 Jan;113(1):181-7. doi: 10.1007/s10549-008-9914-7. Epub 2008 Feb 9. Breast Cancer Res Treat. 2009. PMID: 18264760
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P. Brouckaert O, et al. Among authors: weltens c. Breast Cancer Res Treat. 2009 May;115(2):349-58. doi: 10.1007/s10549-008-0110-6. Epub 2008 Jul 16. Breast Cancer Res Treat. 2009. PMID: 18629635 Clinical Trial.
118 results